참고문헌
- Llovet JM (2004) Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 7, 431-441 https://doi.org/10.1007/s11938-004-0002-8
- Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359, 1734-1739 https://doi.org/10.1016/S0140-6736(02)08649-X
- Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164-1171 https://doi.org/10.1053/jhep.2002.33156
- Murata S, Mine T, Sugihara F et al (2014) Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 20, 13453-13465 https://doi.org/10.3748/wjg.v20.i37.13453
- Shaaban S, Negm A, Ibrahim EE et al (2014) Chemotherapeutic agent for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncol Rev 8, 25-35
- Gupta SC, Kannappan R, Reuter S, Kim JH and Aqqarwal BB (2011) Chemosensitization of tumors by resveratrol. Ann NY Acad Sci 1215, 150-160 https://doi.org/10.1111/j.1749-6632.2010.05852.x
- Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP and Gescher AJ (2005) Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc (Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 115, 194-201 https://doi.org/10.1002/ijc.20884
- Newsholme E, Crabtree B and Ardawi M (1985) The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci Rep 5, 393-400 https://doi.org/10.1007/BF01116556
- Wellen KE, Lu C, Mancuso A et al (2010) The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 24, 2784-2799 https://doi.org/10.1101/gad.1985910
- Kueck A, Opipari AW, Griffith KA et al (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol 107, 450-457 https://doi.org/10.1016/j.ygyno.2007.07.065
- Park JB (2001) Inhibition of glucose and dehydroascorbic acid uptakes by resveratrol in human transformed myelocytic cells. J Nat Prod 64, 381-384 https://doi.org/10.1021/np000411t
- Hwang SO and Lee GM (2008) Nutrient deprivation induces autophagy as well as apoptosis in chinese hamster ovary cell culture. Biotechnol Bioeng 99, 678-685 https://doi.org/10.1002/bit.21589
- Hassan M, Watari H, Abualmaaty A, Ohba Y and Sakuragi N (2014) Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2, 1-23
- Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55 https://doi.org/10.1016/0065-2571(84)90007-4
- Bjorklund M, Roos J, Gogvadze V and Shoshan M (2011) Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment. Cancer Chemother Pharmacol 68, 1459-1467 https://doi.org/10.1007/s00280-011-1640-x
- Desoize B and Madoulet C (2002) Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42, 317-325 https://doi.org/10.1016/S1040-8428(01)00219-0
- Todd RC and Lippard SJ (2009) Inhibition of transcription by platinum antitumor compounds. Metallomics 1, 280-291 https://doi.org/10.1039/b907567d
- Wu YJ, Muldoon LL and Neuwelt EA (2005) The chemoprotective agent N-acetylcysteine blocks cisplatininduced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312, 424-431 https://doi.org/10.1124/jpet.104.075119
- Ma L, Li W, Wang R et al (2015) Resveratrol enhanced anticancer effects of cisplatin on non-small cell lung cancer cell lines by inducing mitochondrial dysfunction and cell apoptosis. Int J Oncol 47, 1460-1468 https://doi.org/10.3892/ijo.2015.3124
- Wang J, He D, Zhang Q, Han Y, Jin S and Qi F (2009) Resveratrol protects against cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother Radiopharm 24, 675-680 https://doi.org/10.1089/cbr.2009.0679
- Simsek G, Tokgoz S, Vuralkan E, Caliskan M, Besalti O and Akin I (2013) Protective effects of resveratrol on cisplatin-dependent inner-ear damage in rats. Eur Arch Otorhinolaryngol 270, 1789-1793 https://doi.org/10.1007/s00405-012-2183-4
- Kim D, Jung Y, Lee J et al (2011) SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol 301, F427-F435 https://doi.org/10.1152/ajprenal.00258.2010
- De Oliveira MR, Nabavi SF, Manayi A, Daglia M, Hajheydari Z and Nabavi SM (2016) Resveratrol and the mitochondria: from triggering the intrinsic apoptotic pathway to inducing mitochondrial biogenesis, a mechanistic view. Biochim Biophys Acta 1860, 727-745 https://doi.org/10.1016/j.bbagen.2016.01.017
- Huang Y, Anderle P, Bussey KJ et al (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64, 4294-4301 https://doi.org/10.1158/0008-5472.CAN-03-3884
- Wise DR and Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends BiochemSci 35, 427-433 https://doi.org/10.1016/j.tibs.2010.05.003
- Bode BP, Fuchs BC, Hurley BP et al (2002) Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol Gastrointest Liver Physiol 283, G1062-1073 https://doi.org/10.1152/ajpgi.00031.2002
- Wang Q, Beaumont KA, Otte NJ et al (2014) Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer 135, 1060-1071 https://doi.org/10.1002/ijc.28749
- Willems L, Jacque N, Jacquel A et al (2013) Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 122, 3521-3532 https://doi.org/10.1182/blood-2013-03-493163
- Hassanein M, Hoeksema MD, Shiota M et al (2013) SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 19, 560-570 https://doi.org/10.1158/1078-0432.CCR-12-2334
- Ren P, Yue M, Xiao D et al (2015) ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol 235, 90-100 https://doi.org/10.1002/path.4429
- Kaira K, Sunose Y, Arakawa K et al (2015) Clinicopathological significance of ASC-amino acid transporter 2 (ASCT2) expression in pancreatic ductal carcinoma. Histopathology 66, 234-243 https://doi.org/10.1111/his.12464
- Brozovic A and Osmak M (2007) Activation of mitogenactivated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251, 1-16 https://doi.org/10.1016/j.canlet.2006.10.007
- Efeyan A and Serrano M (2007) p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6, 1006-1010 https://doi.org/10.4161/cc.6.9.4211
- De Laurenzi V and Melino G (2000) Evolution of functions within the p53/p63/p73 family. Ann NY Acad Sci 926, 90-100
- Kutuk O, Arisan ED, Tezil T, Shoshan MC and Basaga H (2009) Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Carcinogenesis 30, 1517-1527 https://doi.org/10.1093/carcin/bgp165
- Santandreu FM, Valle A, Oliver J and Roca P (2011) Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. Cell Physiol Biochem 28, 219-228 https://doi.org/10.1159/000331733